Estrogen patches are prescription medicines that deliver estrogen through the skin and into the bloodstream. They are used as a form of menopausal hormone therapy for certain symptoms associated with reduced estrogen levels, including hot flashes and night sweats. Some estrogen therapies can also help prevent bone loss after menopause.
An estrogen patch is a transdermal medication. Instead of taking estrogen by mouth, the patch is placed on the skin and releases a measured amount of estrogen into the bloodstream.
Estradiol is a commonly used estrogen in transdermal patches.
Depending on the specific prescription, patches may be designed to be changed once or twice a week. The exact schedule depends on the product and prescription instructions.
Systemic estrogen patches are different from low-dose vaginal estrogen products. Systemic patches deliver estrogen throughout the body, while low-dose vaginal estrogen is primarily intended for local vaginal and urinary symptoms and produces much lower levels of estrogen in the bloodstream.
Menopausal hormone therapy can be used to treat moderate to severe menopause-related symptoms.
Potential reasons for prescribing systemic estrogen include:
Estrogen is considered one of the most effective treatments for bothersome hot flashes and night sweats. Hormone therapy can also help protect bone density while treatment continues.
However, preventing osteoporosis alone may not always justify systemic estrogen in an older woman. Other osteoporosis treatments may be more appropriate depending on fracture risk and medical history.
After application, estrogen passes through the skin and enters the bloodstream.
This provides systemic exposure without requiring the medication to pass through the digestive tract in the same way as an oral tablet.
Transdermal estrogen is also clinically important because the route of administration can affect certain risks. The Menopause Society reports that blood-clot risk may be lower with transdermal estrogen than with oral estrogen, although transdermal treatment is not risk-free.
The patch does not immediately reverse every menopause-related change. Symptom improvement varies between individuals and depends on the dose, formulation, symptoms, and underlying health.
The exact instructions should always come from the prescription label because products differ.
In general, an estrogen patch is applied to clean, dry skin on an approved area of the body.
Common application principles include:
Many estrogen patches are designed for areas such as the lower abdomen or buttocks, but the permitted application site varies by product.
The prescription label should take priority over generalized instructions because applying a particular patch to the wrong location can affect how the medication is absorbed or how well the adhesive works.
Unless the specific product instructions say otherwise, patches should not be placed on irritated, injured, inflamed, or recently treated skin.
Avoid areas where the patch will experience excessive rubbing from clothing.
The patch should also not be placed on the breasts.
Different products have different approved application sites, so the medication label should be checked before each new prescription or brand is used.
A patch can occasionally loosen because of sweating, bathing, friction, or skin conditions.
The appropriate response depends on the particular product.
Some manufacturers instruct patients to reapply the same patch if it remains adhesive and intact. Others provide different instructions.
If the patch will not stick, the product instructions or pharmacist should be consulted rather than applying an additional patch automatically.
Applying two patches to compensate for a patch that has fallen off can result in receiving more estrogen than prescribed.
For products designed for weekly dosing, maintaining a consistent replacement day can help prevent missed doses.
For twice-weekly patches, the prescription generally specifies two particular days separated by several days.
A medication reminder, calendar, or routine household activity can help maintain consistency.
The exact schedule should come from the prescription label.
There is no single estrogen-patch dose that is appropriate for every senior woman.
Dose selection depends on:
Hormone therapy is generally individualized, and treatment should be periodically reassessed.
FDA guidance states that menopausal hormone therapy should be based on an individualized discussion of benefits and risks with a healthcare professional.
Starting systemic hormone therapy after age 60 requires more careful consideration than starting it around the time of menopause.
The Menopause Society states that the benefit-risk balance is generally more favorable for women younger than 60 or within 10 years of menopause onset who are appropriate candidates for treatment. Starting later can involve higher baseline risks for cardiovascular disease, stroke, blood clots, and other conditions.
This does not mean that every woman over 60 must stop hormone therapy.
Some women continue treatment because persistent symptoms significantly affect quality of life. The decision should be individualized rather than based on age alone.
Hormone therapy after age 65 deserves particularly careful review.
A woman who has used hormone therapy for years may have a different situation from someone considering systemic estrogen for the first time at age 70.
Factors that may be reviewed include:
A 2026 report from The Menopause Society emphasized individualized assessment and close monitoring when hormone therapy is initiated or continued in women aged 65 and older.
Systemic estrogen alone can stimulate the lining of the uterus.
For women who still have a uterus, systemic estrogen is generally paired with a progestogen to reduce the risk of endometrial cancer.
Women who have had a hysterectomy may be candidates for estrogen-alone therapy, depending on their medical circumstances.
This distinction is important when discussing estrogen patches because estrogen-alone and estrogen-plus-progestogen therapy have different risk profiles.
FDA information specifically notes the importance of progestogen for women with a uterus who use systemic estrogen.
Estrogen therapy is not appropriate for everyone.
FDA information identifies several situations requiring avoidance or careful evaluation, including a history of certain cancers, unexplained vaginal bleeding, blood clots, stroke, heart attack, liver disease, bleeding disorders, or serious reactions to estrogen medicines.
A history of these conditions does not mean that every form of estrogen treatment has identical risks. Local vaginal estrogen and systemic estrogen have different exposure levels and indications.
Medical evaluation is therefore important before starting or changing hormone therapy.
Some women experience side effects after starting systemic estrogen.
Possible effects include:
Some side effects may improve after the body adjusts to treatment.
Persistent or troublesome symptoms should be discussed with the prescribing clinician rather than changing the dose independently.
Certain symptoms can indicate a serious complication.
Urgent medical attention may be necessary for symptoms such as:
These symptoms can have causes unrelated to hormone therapy, but they should not be ignored.
Blood-clot risk is an important consideration with systemic hormone therapy.
The Menopause Society notes that blood-clot risk increases with oral hormone therapy and may be lower with transdermal estrogen, such as patches, gels, or sprays.
Lower does not mean zero.
Age itself can increase the baseline risk of blood clots, and other factors such as previous clots, obesity, smoking, immobility, surgery, and certain medical conditions can further affect risk.
A history of blood clots should therefore be discussed before systemic hormone therapy is considered.
Breast-cancer risk associated with hormone therapy depends on factors such as the type of therapy, duration, and individual circumstances.
Estrogen-alone therapy and combined estrogen-progestogen therapy do not have identical risk profiles.
The Menopause Society reports that breast-cancer considerations differ between estrogen-alone therapy and estrogen-plus-progestogen therapy.
The FDA's 2026 labeling updates removed certain cardiovascular disease, breast-cancer, and probable dementia statements from the boxed warnings of some menopausal hormone therapy products, but the agency retained breast-cancer and cardiovascular information elsewhere in prescribing information. This does not mean those risks have disappeared.
Estrogen helps maintain bone density.
After menopause, declining estrogen contributes to increased bone loss.
Systemic hormone therapy can reduce bone loss and fracture risk while treatment continues. FDA-approved estrogen products can be prescribed for prevention of postmenopausal osteoporosis in appropriate circumstances.
However, hormone therapy is not necessarily the first treatment selected solely for osteoporosis in an older woman.
A bone-density assessment and overall fracture-risk evaluation can help determine whether osteoporosis-specific medication, calcium and vitamin D intake, resistance exercise, fall prevention, or other measures are appropriate.
Systemic estrogen can improve some vaginal and urinary symptoms associated with menopause.
However, women whose symptoms are limited primarily to vaginal dryness, discomfort, or certain urinary symptoms may sometimes be treated with low-dose vaginal estrogen instead of systemic hormone therapy.
Low-dose vaginal estrogen produces much lower systemic exposure than systemic hormone therapy and has a different risk-benefit profile.
The appropriate formulation depends on the symptoms and medical history.
Both pills and patches can provide systemic estrogen, but the route of administration differs.
An estrogen patch delivers hormone through the skin, whereas an oral tablet passes through the digestive system before reaching the circulation.
One important difference concerns blood-clot risk. Transdermal estrogen may have a lower clot risk than oral estrogen, although individual risk factors remain important.
The route alone does not determine whether hormone therapy is safe.
There is no universal duration that applies to every woman.
Some women use hormone therapy for a relatively short period, while others continue treatment because symptoms remain significant.
Long-term therapy should be periodically reviewed.
The decision can involve:
Stopping or reducing a prescription should be discussed with the prescribing clinician rather than done suddenly without medical advice.
A medical appointment before starting treatment may include questions about:
This information helps determine whether systemic estrogen is appropriate and which formulation may be safest.
Estradiol transdermal patches have also been subject to recent supply concerns in the United States.
On September 3, 2026, the FDA reported that some patients had difficulty obtaining their usual estradiol patches because of increased demand. The agency stated that manufacturers were increasing production and advised patients not to stop or change treatment without speaking with a healthcare professional.
If a particular patch cannot be obtained, a pharmacist or prescriber can determine whether another FDA-approved estradiol product is medically appropriate.